Page 7 - Lymphoma Program News Today

/PRNewswire/ -- Novartis today announced robust data from the primary analysis of the pivotal Phase II ELARA trial of Kymriah® (tisagenlecleucel) in patients...

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma

Date Time Researchers Uncover How MN1 Overexpression Causes AML Meningioma-1 (MN1) is a protein whose overexpression has been linked to acute myeloid leukemia (AML) and brain tumors, and 70% to 80% of AML patients with high overexpression of MN1 die within two years. Yet the mechanism by which MN1 causes these diseases has largely remained a mystery. “Looking at the sequence, the protein has no obvious structure,” said Kathrin M. Bernt, MD, a pediatric oncologist in the Cancer Center’sLeu...

Date Time Less is More for Next Generation of CAR T Cells PHILADELPHIA—When researchers from Penn Medicine found that many patients with B-cell acute lymphoblastic leukemia (ALL) treated with the investigational chimeric antigen receptor (CAR) T cell therapy targeting the CD22 antigen didn’t respond, they went back to the drawing board to determine why. They discovered that less is more when it comes to the length of what is known as the single-chain variable fragment — the linker that br...

PHILADELPHIA--When researchers from Penn Medicine found that many patients with B-cell acute lymphoblastic leukemia (ALL) treated with the investigational chimeric antigen receptor (CAR) T cell therapy targeting the CD22 antigen didnt respond, they went back to the drawing board to determine why. They discovered that less is more when it comes to the length of what is known as the single-chain variable fragment -- the linker that bridges the two halves of the receptor that allows CAR T cells t...

Study reveals extremely low detection of SARS-CoV-2 on surfaces in oncology facilities Researchers from Rutgers Cancer Institute of New Jersey, the states only National Cancer Institute-designated Comprehensive Cancer Center, evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health faci...

The finding provides additional assurance that those receiving cancer care are safe when receiving care. “For patients with blood cancers who may be at higher risk of developing complications from the virus, our findings provide a layer of assurance that these patients are safe when frequenting high impact areas where they receive their cancer care,” says Andrew Evens, the lead author of the study published in Cancer, director of the Lymphoma Program at Rutgers Cancer Institute of New Jers...

Five years later: CAR T therapy shows long-lasting remissions in non-Hodgkin lymphomas Findings represent the longest follow-up data to date for a personalized cellular therapy approved by the FDA for the treatment of aggressive lymphomas. A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah™, researchers...

Researchers from Rutgers Cancer Institute of New Jersey, the state's only National Cancer Institute-designated Comprehensive Cancer Center, evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility.

 E-Mail PHILADELPHIA--A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah™, researchers in Penns Abramson Cancer Center reported today in the New England Journal of Medicine. The findings represent the longest follow-up, published data to date for CAR T cell therapies approved by the U.S. Food and Drug Administration for the tr...